Abstract PO2-18-04: STX-478 is a Potentially Best-in-class Mutant-Selective PI3Kα Inhibitor That Demonstrates Robust Efficacy in ER+ Breast Cancer Models As Monotherapy and in Combination with Standard of Care Agents